Over 200% Stock Upside – Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst – Vanda Pharma (NASDAQ:VNDA)
HC Wainwright initiated coverage on Vanda Pharmaceuticals, Inc. VNDA, a commercial-stage biopharmaceutical firm primarily focusing on neurological and neuropsychiatry disorders. HC Wainwright sees Vanda as having a well-established commercial portfolio,…